The FDA has approved Helixate FS (antihemophilic factor VIII [recombinant], from CSL Behring) for routine prophylaxis in children with hemophilia A who are ≤16 years of age and do not have pre-existing joint damage. This new indication was granted by the FDA after determining Helixate FS to be safe and effective for routine prophylaxis, which can reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A.

Helixate FS is already indicated for the prevention and control of bleeding episodes in adults and for surgical prophylaxis in adults and children with Hemophilia A.

For more information call (800) 504-5434 or visit www.helixatefs.com.